BRIDGEBIO PHARMA INC (BBIO) Forecast, Price Target & Analyst Ratings

NASDAQ:BBIO • US10806X1028

Current stock price

69.6 USD
+1.06 (+1.55%)
At close:
69.6 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BRIDGEBIO PHARMA INC (BBIO).

Forecast Snapshot

Consensus Price Target

Price Target
$99.16
+ 42.46% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
Apr 27, 2026
Period
Q1 / 2026
EPS Estimate
-$0.70
Revenue Estimate
181.81M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
85.00%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$99.16
Upside
+ 42.46%
From current price of $69.60 to mean target of $99.16, Based on 28 analyst forecasts
Low
$68.11
Median
$97.92
High
$164.85

Price Target Revisions

1 Month
4.77%
3 Months
16.30%

Price Target Summary

28 Wall Street analysts provided a forecast for the next 12 months for BBIO. The average price target is 99.16 USD. This implies a price increase of 42.46% is expected in the next year compared to the current price of 69.6.
The average price target has been revised upward by 16.3% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

BBIO Current Analyst RatingBBIO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 5 10 15

Analyst Ratings History

BBIO Historical Analyst RatingsBBIO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20 25

Analyst Ratings Consensus

ChartMill Buy Consensus
85.00%
BBIO was analyzed by 28 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about BBIO.
In the previous month the buy percentage consensus was at a similar level.
BBIO was analyzed by 28 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-18MizuhoMaintains Outperform -> Outperform
2026-03-10William BlairInitiate Outperform
2026-03-10JP MorganMaintains Overweight -> Overweight
2026-02-25OppenheimerMaintains Outperform -> Outperform
2026-02-25Evercore ISI GroupMaintains Outperform -> Outperform
2026-02-25Truist SecuritiesMaintains Buy -> Buy
2026-02-25Morgan StanleyMaintains Overweight -> Overweight
2026-02-17HC Wainwright & Co.Maintains Buy -> Buy
2026-02-13OppenheimerMaintains Outperform -> Outperform
2026-02-13Wells FargoMaintains Overweight -> Overweight
2026-01-28BarclaysInitiate Overweight
2026-01-20Wells FargoMaintains Overweight -> Overweight
2026-01-08Truist SecuritiesMaintains Buy -> Buy
2026-01-06Morgan StanleyInitiate Overweight
2025-12-15Leerink PartnersMaintains Outperform -> Outperform
2025-12-11BernsteinInitiate Outperform
2025-11-11Wells FargoMaintains Overweight -> Overweight
2025-11-07JP MorganMaintains Overweight -> Overweight
2025-11-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-10-31Goldman SachsMaintains Buy -> Buy
2025-10-30TD CowenMaintains Buy -> Buy
2025-10-30Cantor FitzgeraldMaintains Overweight -> Overweight
2025-10-30Raymond JamesReiterate Outperform -> Outperform
2025-10-30Truist SecuritiesReiterate Buy -> Buy
2025-10-30Piper SandlerMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
Apr 27, 2026
Period
Q1 / 2026
EPS Estimate
-$0.70
Revenue Estimate
181.81M
Revenue Q2Q
55.88%
EPS Q2Q
19.91%
Number of Analysts
18

Next Earnings Revisions

Revenue (1 Month)
9.37%
Revenue (3 Months)
7.77%
EPS (1 Month)
-1.25%
EPS (3 Months)
-1.89%

Next Earnings Summary

BBIO is expected to report earnings on 4/27/2026. The consensus EPS estimate for the next earnings is -0.7 USD and the consensus revenue estimate is 181.81M USD.
The next earnings revenue estimate has been revised upward by 7.77% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
BBIO revenue by date.BBIO revenue by date.
9.303M
-88.02%		221.902M
2,285.27%		502.076M
126.26%		944.72M
88.16%		1.645B
74.13%		2.425B
47.42%		3.307B
36.37%		4.128B
24.83%		4.954B
20.01%		5.611B
13.26%		6.049B
7.81%
EBITDA
YoY % growth
BBIO ebitda by date.BBIO ebitda by date.
-592.95M
-28.44%		-571.293M
3.65%		-496.63M
13.07%		-265.116M
46.62%		258.16M
197.38%		640.03M
147.92%		639.54M
-0.08%		1.113B
74.03%		1.592B
43.04%		2.017B
26.70%		2.39B
18.49%
EBIT
YoY % growth
BBIO ebit by date.BBIO ebit by date.
-599.444M
-27.97%		-577.368M
3.68%		-502.064M
13.04%		-274.777M
45.27%		256.99M
193.53%		911.06M
254.51%		1.551B
70.24%		2.261B
45.78%		2.851B
26.09%		3.407B
19.50%		3.785B
11.09%
Operating Margin
BBIO operating margin by date.BBIO operating margin by date.
-6,443.56%-260.19%-100.00%-29.09%15.62%37.57%46.90%54.77%57.55%60.72%62.57%
EPS
YoY % growth
BBIO eps by date.BBIO eps by date.
-3.94
-26.69%		-3.09
21.57%		-3.78
-22.33%		-1.88
50.16%		0.63
133.68%		3.86
508.75%		6.74
74.54%		12.70
88.35%		12.04
-5.22%		13.13
9.07%		12.26
-6.60%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26
EPS
Q2Q % growth		-0.70
19.91%		-0.55
42.21%		-0.49
48.46%		-0.34
65.55%
Revenue
Q2Q % growth		181.81M
55.88%		210.56M
90.44%		221.48M
83.50%		266.31M
72.73%
EBITDA
Q2Q % growth		-110.667M
-7.95%		-79.567M
39.20%		-38.534M
70.89%		N/A
EBIT
Q2Q % growth		-106.066M
-2.18%		-80.758M
39.49%		-67.61M
50.42%		-37.099M
71.11%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

BBIO Yearly Revenue VS EstimatesBBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
BBIO Yearly EPS VS EstimatesBBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
44.58%
EPS Next 5 Year
39.90%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
68.44%
Revenue Next 5 Year
52.08%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
48.24%
EBIT Next 5 Year
33.16%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

BRIDGEBIO PHARMA INC / BBIO Forecast FAQ

Can you provide the average price target for BRIDGEBIO PHARMA INC stock?

28 analysts have analysed BBIO and the average price target is 99.16 USD. This implies a price increase of 42.46% is expected in the next year compared to the current price of 69.6.

What is the next earnings date for BBIO stock?

BRIDGEBIO PHARMA INC (BBIO) will report earnings on 2026-04-27.

Can you provide the consensus estimates for BRIDGEBIO PHARMA INC next earnings?

The consensus EPS estimate for the next earnings of BRIDGEBIO PHARMA INC (BBIO) is -0.7 USD and the consensus revenue estimate is 181.81M USD.

Can you provide the consensus rating for BRIDGEBIO PHARMA INC stock?

The consensus rating for BRIDGEBIO PHARMA INC (BBIO) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.